根据名称进行药物检索

Coumadin Injection 与 Oruvail

Coumadin Injection 与 Oruvail互相作用以及同时服用的可能性。

检测结果:

Coumadin Injection <> Oruvail

现实性: 28.05.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前使用洛芬和华法林. 使用洛芬一起华法林可能会导致你流血更容易。你可能需要调整剂量的基础上你的凝血酶原时间或国际标准化比率(印度). 叫你的医生及时如果你有任何不寻常或出血瘀伤、呕吐、血液在你的尿液或凳子、头疼、头晕、或弱点。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：非甾体抗炎药(非甾体抗炎药)可能促进hypoprothrombinemic的效果和流血的风险相关联的口服抗凝血剂。在一年的观察研究的一个人口的香豆素的用户的相对风险的出血并发症，由于伴随的非甾体的使用是5.8相比，香豆素单独使用。一些调查显示，风险胃溃疡出血性特别可以大大增加，特别是在年老或体弱的病人。回顾性的流行病学研究的患者年龄在65岁或以上报告了近13倍增加的风险胃溃疡出血性疾病并发用户的口服抗凝血剂和非甾体抗炎药相比，非使用者的药物。死亡人数已上报。在药理作用的药物，有助于这种相互作用，包括肠胃刺激，延长的凝血酶原时间，抑制血小板粘合力和凝聚。此外，各种非甾体抗炎药也已显示出改变的药物动力学的华法林和其它口腔抗凝血剂，从而增加的印度卢比或凝血酶原时间。然而，一些研究未能证明任何证据证明的相互作用。

管理：非甾体抗炎药应用口服抗凝血剂的只有当受益远远超过风险。印度卢比应当经常检查和口服抗凝血剂量进行相应的调整，特别是以下启动或中止的非甾体抗炎药的病人稳定对他们的抗凝血剂方案。患者应立即报告任何不寻常或出血瘀伤到他们的医生，包括疼痛、肿、头疼、头晕、弱点、出血时间延长，从削减，增加经流，阴道出血、流鼻血，止血的牙龈从刷、红色或棕色的尿液或红色或黑色的大便。水杨酸(除了阿司匹林)的出现为具有的影响较小，在凝结的和可能优于治疗的患者用口服抗凝血剂。尽管如此，谨慎建议，并密切监测对于胃肠出血的建议，特别是在年老或体弱的病人。

来源

Loftin JP, Vesell ES "Interaction between sulindac and warfarin: different results in normal subjects and in an unusual patient with a potassium-losing renal tubular defect." J Clin Pharmacol 19 (1979): 733-42
Gabb GM "Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug." Med J Aust 164 (1996): 700-1
Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R "Main comedications associated with major bleeding during anticoagulant therapy with coumarins." Eur J Clin Pharmacol 61 (2005): 439-44
Flessner MF, Knight H "Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen." JAMA 259 (1988): 353
Brouwers JRBJ, Desmet PAGM "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet 27 (1994): 462-85
Self TH, Soloway MS, Vaughn D "Possible interaction of indomethacin and warfarin." Drug Intell Clin Pharm 12 (1978): 580-2
Bull J, Mackinnon J "Phenylbutazone and anticoagulant control." Practitioner 215 (1975): 767-72
Stricker BH, Delhez JL "Interaction between flurbiprofen and courmarins." Br Med J 285 (1982): 812-3
Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58
O'Reilly RA, Goulart DA "Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin." J Pharmacol Exp Ther 219 (1981): 691-4
Pardo A, GarciaLosa M, FernandezPavon A, delCastillo S, PascualGarcia T, GarciaMendez E, DalRe R "A placebo-controlled study of interaction between nabumetone and acenocoumarol." Br J Clin Pharmacol 47 (1999): 441-4
Serlin MJ, Breckenridge AM "Drug interactions with warfarin." Drugs 25 (1983): 610-20
Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckeridge AM "Interaction between diflunisal and warfarin." Clin Pharmacol Ther 28 (1980): 493-8
Davis LJ, Kayser SR, Hubsher J, Williams RL "Effect of oxaprozin on the steady-state anticoagulant activity of warfarin." Clin Pharm 3 (1984): 295-7
"Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
Rhodes RS, Rhodes PJ, Klein C, Sintek CD "A warfarin-piroxicam drug interaction." Drug Intell Clin Pharm 19 (1985): 556-8
O'Reilly RA "Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon." Arch Intern Med 142 (1982): 1634-7
Udall JA "Drug interference with warfarin therapy." Clin Med 77 (1970): 20-5
Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6
Knijff-Dutmer EA, Schut GA, van de Laar MA "Concomitant coumarin-NSAID therapy and risk for bleeding." Ann Pharmacother 37 (2003): 12-6
Mieszczak C, Winther K "Lack of interaction of ketoprofen with warfarin." Eur J Clin Pharmacol 44 (1993): 205-6
Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988): 483-8
Buchanan GR, Martin V, Levine PH, et al "The effects of "anti-platelet" drugs on bleeding time and platelet aggregation in normal human subjects." Am J Clin Pathol 68 (1977): 355-9
Held H, Kaminski B, von Oldersausen HF "Die beeinflussung der elimination von glycodiazin durch leber- und nierenfunctionssorungen und durch eine behandlung mit phenylbutazone, phenprocumarol und doxycyclin." Diabetologia 6 (1970): 386-91
Dahl SL, Ward JR "Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent." Pharmacotherapy 2 (1982): 80-9
Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83
Aggeler PM, O'Reilly RA, Leong L, Kowitz PE "Potentiation of anticoagulant effect of warfarin by phenylbutazone." N Engl J Med 276 (1967): 496-501
Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ "Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin." Clin Pharmacol Ther 55 (1994): 305-16
Schulman S, Henriksson K "Interaction of ibuprofen and warfarin on primary haemostasis." Br J Rheumatol 28 (1989): 46-9
Schafer AI "Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis." J Clin Pharmacol 35 (1995): 209-19
Shorr RI, Ray WA, Daugherty JR, Griffin MR "Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease." Arch Intern Med 153 (1993): 1665-70
Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94
Self TH, Evans WE, Ferguson T "Drug enhancement of warfarin activity." Lancet 2 (1975): 557-8
Koren JF, Cochran DL, Janes RL "Tolmetin-warfarin interaction." Am J Med 82 (1987): 1278-80
Dennis VC, Thomas BK, Hanlon JE "Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone." Pharmacotherapy 20 (2000): 234-9